Before joining Terremoto, Baum was the founder, president and CEO of Mirati Therapeutics, and oversaw the company’s' sale to Bristol Myers Squibb last year.

Prior to his tenure at Mirati, Baum held positions at Pfizer and Schering Plough as well as academic and clinical positions at institutions such as Stanford and Emory Universities. Baum holds an M.D. and a Ph.D. from Washington University School of Medicine and completed his post-graduate training at Stanford University.

“Chuck has a legacy of successful leadership in precision therapeutics, most recently at Mirati Therapeutics, where under his guidance, the company was transformed and went on to create compelling pipeline value that led to an acquisition by Bristol Meyers Squibb for up to $5.8 billion,” said Thompson. “I’m honored to hand the reins over to him as the leader of Terremoto. His extensive experience in drug development, and proven track record in advancing high-impact medicines, will be instrumental as we continue to develop treatments that promise superior therapeutic benefit to patients.”